As of the latest Form 4 filed Jul 7, 2026.
What Monte Rosa Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 30 most recent filings for GLUE.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-06 | Townson Sharon Chief Scientific Officer | SSale | −400.00 | $24.13 | $9.65K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-06 | Townson Sharon, Chief Scientific Officer | SSale | −5.60K | $23.25 | $130K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-06 | Townson Sharon, Chief Scientific Officer | MExercise | +6.00K | $6.14 | $36.8K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Janku Filip Chief Medical Officer | SSale | −5.41K | $24.50 | $132K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Janku Filip, Chief Medical Officer | MExercise | +5.41K | $13.41 | $72.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Janku Filip Chief Medical Officer | SSale | −6.00K | $22.95 | $138K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Janku Filip, Chief Medical Officer | MExercise | +6.00K | $7.56 | $45.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Manning Anthony M. Director | SSale | −10.0K | $23.11 | $231K | No | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Manning Anthony M., Director | MExercise | +10.0K | $4.16 | $41.6K | No | Form 4 ↗ |
| 2026-06-25 | 2026-06-24 | Janku Filip Chief Medical Officer | SSale | −30.0K | $21.42 | $643K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-24 | Janku Filip, Chief Medical Officer | MExercise | +30.0K | $7.56 | $227K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Janku Filip, Chief Medical Officer | SSale | −11.8K | $20.22 | $240K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Janku Filip, Chief Medical Officer | MExercise | +6.00K | $7.56 | $45.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Townson Sharon Chief Scientific Officer | SSale | −3.00K | $20.00 | $60.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Townson Sharon, Chief Scientific Officer | MExercise | +3.00K | $6.14 | $18.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Champoux Jennifer Chief Operating Officer | SSale | −2.17K | $20.00 | $43.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-23 | Champoux Jennifer, Chief Operating Officer | MExercise | +2.17K | $3.98 | $8.66K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Champoux Jennifer Chief Operating Officer | SSale | −2.18K | $19.00 | $41.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Champoux Jennifer, Chief Operating Officer | MExercise | +2.18K | $3.98 | $8.66K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Townson Sharon Chief Scientific Officer | SSale | −3.00K | $19.00 | $57.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Townson Sharon, Chief Scientific Officer | MExercise | +3.00K | $6.14 | $18.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Warmuth Markus President & CEO | SSale | −468.00 | $19.73 | $9.23K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Warmuth Markus, President & CEO | SSale | −5.00K | $19.41 | $97.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | Townson Sharon Chief Scientific Officer | SSale | −6.00K | $19.87 | $119K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | Townson Sharon, Chief Scientific Officer | MExercise | +6.00K | $6.14 | $36.8K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-27 | Champoux Jennifer Chief Operating Officer | SSale | −2.17K | $20.00 | $43.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-27 | Champoux Jennifer, Chief Operating Officer | MExercise | +2.17K | $3.98 | $8.66K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | Warmuth Markus President & CEO | SSale | −8.00K | $17.64 | $141K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-09 | Nickson Philip Chief Business & Legal Officer | SSale | −5.84K | $17.69 | $103K | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-06 | Bowen Matthew Principal Accounting Officer | AAward | +4.30K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also GLUE’s full analysis or the market-wide insider trading feed. The tabs above jump to GLUE’s other SEC data.
Source: SEC Form 4 filings for GLUE, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.